Cancer Focus Fund II, LP

Ross Barrett is the sole named GP on file, a structure that concentrates decision rights and creates key-person dependency; the absence of prior EDGAR filings under this manager's name suggests either a newly independent operator or a previously lower-profile manager now raising at scale, both scenarios requiring LP due diligence on Barrett's prior fund track record and operational depth to support a $250M vehicle.

Filing an amendment in May 2026 after closing only $23M (9% of target) signals either an extension of the initial fundraise window due to slower LP commitments, or a pivot in terms and marketing to accelerate pace—either scenario flags that momentum has not been automatic and LPs should assess whether fund positioning in cancer-focused venture reflects current allocation appetite or a niche strategy with constrained demand.

Verify whether Ross Barrett is subject to a key-person clause tied to the fund's ability to deploy and manage exits, and confirm whether the 3C.7 structure imposes LP-level restrictions on who can invest or co-invest alongside the fund—both features materially change the risk profile and should be reconciled with any side letter or commitment letter terms before LP commitment.